Frequently asked questions :
COVID-19 has considerably impacted the market due to the growing number of cases, lockdown implications imposed by the government, and a reduced number of elective surgeries.
North America accounted for the largest market share of the global Liquid Biopsy market.
Increasing demand for cancer testing, growing investments, and rising R&D activities to drive the Liquid Biopsy market.
The NGS segment had a major share of the global market in 2022.
The ROU segment had a major share in the global market.